Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ACTRN12619000743167
ACTRN12619000743167Active, not recruiting未知

A pilot study of Video Assisted Thoracic Surgery (VATS) fissure completion prior to Zephyr® Endobronchial Valve insertion for severe Chronic Obstructive Pulmonary Disease (COPD) in patients with COllateral VEntilation

Pulmonx Australia Pty. Ltd.0 sites9 target enrollmentStarted: May 20, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Sponsor
Enrollment
9
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment

Eligibility Criteria

Ages
40 Years to o limit (—)
Sex
All

Inclusion Criteria

  • •1. Subject is willing and able to provide informed consent and to participate in the study.
  • •2. Subject is greater than or equal to 40 years of age.
  • •3. Subject has a diagnosis of severe or very severe homogenous or heterogeneous COPD (GOLD classification1).
  • •4. Subject has a post bronchodilator FEV1 of greater than or equal to 15% and less than or equal to 50%.
  • •5. Subject has TLC > 100% predicted.
  • •6. Subject has RV > 175% predicted.
  • •7. Subject has a normal dobutamine stress echocardiogram.
  • •8. Subject has sufficient exercise tolerance i.e. 6MWT is greater than or equal to 150m and less than or equal to 450m.
  • •9. Subject has an incomplete lobar fissure i.e. < 90%, as confirmed by CT evaluation of lung fissures.
  • •10. Collateral ventilation confirmed as assessed by Chartis Assessment (to be confirmed during first procedure/operation)
  • •11. Subject has stopped smoking for at least 8 weeks prior to entering the study as confirmed by carboxyhaemoglobin or cotinine levels.
  • •12. Subject is up to date with preventive vaccinations including seasonal influenza vaccine and pneumococcal vaccine consistent with the Victorian Department of Health and Human Services Immunisation Schedule Guidelines (updated March 2018).

Exclusion Criteria

  • •1. Subject has a history of previous thoracotomy, lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung transplantation, prior airway stent placement, prior pleurodesis, or prior endobronchial lung volume reduction therapy of any form.
  • •2. Subject has an acute COPD exacerbation.
  • •3. Subject has evidence of active respiratory infection.
  • •4. Subject has a post bronchodilator FEV1 < 15%.
  • •5. Subject has a DLCO < 20%.
  • •6. Subject has a history of recurrent clinically significant respiratory infections, defined as three (3) or more COPD exacerbations requiring hospitalisation during the 12 months prior to study enrolment (ICF signature page).
  • •7. Subject has severe gas exchange abnormalities as defined by any one of the following:
  • •a. PaO2 < 60 mmHg
  • •b. PaCO2 > 45 mmHg on room air
  • •c. SpO2 < 90% on less than or equal to 4 L/min supplemental O2 at rest
  • •8. Subject use of systemic steroids > 20mg/day or equivalent and/or immunosuppressive agents in the 4 weeks prior to procedure.
  • •9. Subject unable to temporarily interrupt use of heparins or oral anticoagulants or antiplatelet agents, excluding aspirin.
  • •10. Subject’s pre-operative CT scan indicates the presence of any of the following radiological abnormalities:
  • •a. Pulmonary nodule is greater than or equal to 0.8 cm in diameter (does not apply if present for 2 years or more without increase in size or if proven benign by biopsy/PET).
  • •b. Radiological picture consistent with active pulmonary infection, e.g. unexplained parenchymal infiltrate.
  • •c. Giant bullae > 30% of the volume of either lung.
  • •d. Significant interstitial lung disease.
  • •e. Significant pleural disease.
  • •11. Subject’s baseline ECG demonstrates clinically significant arrhythmias or conduction abnormalities.
  • •12. Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis.
  • •13. Subject has a known diagnosis of alpha-1 antitrypsin deficiency.
  • •14. Subject is classified as having likely” pulmonary hypertension defined as tricuspid regurgitation velocity > 3.4m/s and/or pulmonary artery peak systolic pressure > 45 mmHg on echocardiogram or a previous formal diagnosis of pulmonary hypertension on right heart catheterization.
  • •15. Subject has suspected significant coronary artery disease defined as regional wall motion abnormalities on dobutamine stress echocardiogram.
  • •16. Subject is classified as being at major cardiac risk with the presence of unstable coronary syndromes (i.e. unstable or severe angina or recent myocardial infarct), decompensated heart failure, significant arrhythmias or severe valvular disease, which warrants intensive management of the condition in accordance with current guidelines on perioperative cardiovascular risk.

Investigators

Sponsor
Pulmonx Australia Pty. Ltd.

Similar Trials

Completed
Not Applicable
Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve InsertionPulmonary Emphysema
NCT04465461Pulmonx Corporation9
Not yet recruiting
Phase 2
Empyema of Lung treatment.
CTRI/2018/08/015361AIIMS Rishikesh
Completed
Not Applicable
Effects of Surgery Types in Patients With Pulmonary NodulesPulmonary Nodule
NCT04805723Gazi University27
Recruiting
Not Applicable
Pediatric Video Assisted Thoracoscopic Surgery (VATS) in Management of EmpyemaThoracic Empyema
NCT06424457Assiut University73
Unknown
Phase 3
Clinical Trial of Thoracoscopic Bullectomy Surgery Under Spontaneous Ventilating AnesthesiaStability During Surgical OperationComplication, PostoperativePostoperative Hospitalization Time
NCT03016858Guangzhou Institute of Respiratory Disease320
A pilot study of Video Assisted Thoracic... | Clinical Trial